BioAffinity Technologies Valuation
| BIAF Stock | USD 1.18 0.05 4.07% |
Today, the firm appears to be undervalued. bioAffinity Technologies shows a prevailing Real Value of $2.37 per share. The current price of the firm is $1.18. Our model approximates the value of bioAffinity Technologies from analyzing the firm fundamentals such as Current Valuation of (1.68 M), operating margin of (1.59) %, and Return On Equity of -2.45 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that BioAffinity Technologies' price fluctuation is dangerous at this time. Calculation of the real value of bioAffinity Technologies is based on 3 months time horizon. Increasing BioAffinity Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioAffinity stock is determined by what a typical buyer is willing to pay for full or partial control of bioAffinity Technologies. Since BioAffinity Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioAffinity Stock. However, BioAffinity Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.18 | Real 2.37 | Hype 1.01 | Naive 1.04 |
The real value of BioAffinity Stock, also known as its intrinsic value, is the underlying worth of bioAffinity Technologies Company, which is reflected in its stock price. It is based on BioAffinity Technologies' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioAffinity Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of bioAffinity Technologies helps investors to forecast how BioAffinity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioAffinity Technologies more accurately as focusing exclusively on BioAffinity Technologies' fundamentals will not take into account other important factors: BioAffinity Technologies Total Value Analysis
bioAffinity Technologies is currently forecasted to have valuation of (1.68 M) with market capitalization of 5.31 M, debt of 1.5 M, and cash on hands of 214.4 K. The negative valuation of BioAffinity Technologies may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the BioAffinity Technologies fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.68 M) | 5.31 M | 1.5 M | 214.4 K |
BioAffinity Technologies Investor Information
The company has price-to-book (P/B) ratio of 0.6. Some equities with similar Price to Book (P/B) outperform the market in the long run. bioAffinity Technologies recorded a loss per share of 13.83. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 19th of September 2025. Based on the key indicators related to BioAffinity Technologies' liquidity, profitability, solvency, and operating efficiency, bioAffinity Technologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.BioAffinity Technologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioAffinity Technologies has an asset utilization ratio of 143.73 percent. This implies that the Company is making $1.44 for each dollar of assets. An increasing asset utilization means that bioAffinity Technologies is more efficient with each dollar of assets it utilizes for everyday operations.BioAffinity Technologies Ownership Allocation
bioAffinity Technologies shows 3.15 percent of its outstanding shares held by insiders and 9.35 percent owned by other corporate entities.BioAffinity Technologies Profitability Analysis
The company reported the previous year's revenue of 9.36 M. Net Loss for the year was (9.04 M) with profit before overhead, payroll, taxes, and interest of 1.89 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BioAffinity Technologies' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BioAffinity Technologies and how it compares across the competition.
About BioAffinity Technologies Valuation
The stock valuation mechanism determines BioAffinity Technologies' current worth on a weekly basis. Our valuation model uses a comparative analysis of BioAffinity Technologies. We calculate exposure to BioAffinity Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioAffinity Technologies's related companies.bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Complementary Tools for BioAffinity Stock analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |